Blood filter on ECMO may cut drug doses in heart shock
NCT ID NCT05027529
First seen Feb 04, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tested whether adding a special blood filter (CytoSorb) to a heart-lung machine (ECMO) helps people in severe heart failure (cardiogenic shock). 42 adults were randomly assigned to get ECMO with or without the filter. The main goal was to see if the filter reduced the amount of heart-supporting drugs needed after 72 hours. The trial is complete, but results are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Jena University Hospital, Department of Cardiology
Jena, Thuringia, 07747, Germany
Conditions
Explore the condition pages connected to this study.